SCHEMBL16307669

SCHEMBL16307669

C=C1C=CC(=O)N1CCC(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 8/20 0.40
FAAH O00519 4/20 0.40
ALDH1A1 P00352 4/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
GMNN O75496 1/20 0.40
THPO P40225 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
TLR9 Q9NR96 2/20 0.39
HSP90AA1 P07900 1/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39
XBP1 P17861 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14868088 0.89 MGLL (0.47) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL406705 0.87 MGLL (0.50) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL17170573 0.86 MGLL (0.52) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL14868093 0.86 MGLL (0.52) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL14868091 0.86 MGLL (0.52) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL3482800 0.86 MGLL (0.54) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL14868092 0.82 MGLL (0.44) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL17190596 0.79 MGLL (0.56) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL12056284 0.78 MGLL (0.50) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL19105008 0.77 ALDH1A1 (0.38) ALDH1A1LMNAMAPTPKMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9862682-B2 Functionalized pegylated cyanine compounds, pharmaceutical compositions, and methods of use thereof BroadPharm (US) 2018-01-09 US disclosed
US-20170197916-A1 FUNCTIONALIZED PEGYLATED CYANINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF BroadPharm (US) 2017-07-13 US disclosed
US-9579367-B2 C-terminally tethered amino acids and their fibrinolytic therapeutic uses CANADIAN BLOOD SERVICES (CA) 2017-02-28 US disclosed
US-20140369992-A1 C-Terminally Tethered Amino Acids and Their Fibrinolytic Therapeutic Uses CANADIAN BLOOD SERVICES (CA) 2014-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197916-A1 FUNCTIONALIZED PEGYLATED CYANINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF ABL1, EGFR, ALB MGLL 1481/4885FAAH 3047/4885ALDH1A1 1441/4885
US-20140369992-A1 C-Terminally Tethered Amino Acids and Their Fibrinolytic Therapeutic Uses HABP2, FGB, PROC MGLL 2673/4885FAAH 1386/4885ALDH1A1 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.